Claims
- 1. A method of treating sexual dysfunction in a female mammal in need of such treatment which comprises administering to said female a therapeutically effective amount of a compound which acts upon a mid-brain pathway to increase blood flow in the ilio-hypogastric-pudendal arterial bed and genitalia.
- 2. The method of claim 1 wherein said compound acts upon a mid-brain dopaminergic pathway.
- 3. A method according to claim 2 wherein said compound acting upon a mid-brain dopaminergic pathway is selected from the group consisting of apomorphine, bromocriptine, lisuride, methergoline, pergolide, pribidil and quinapril or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 4. The method of claim 1 wherein said compound acts upon a mid-brain serotonergic pathway
- 5. A method according to claim 4 wherein said compound acting upon a mid-brain serotonergic pathway is selected from the group consisting of 1-(2,5-dimethoxy-4-iodophenyl)-1-aminopropane, 5-methoxytryptamine, α-methyl-5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine, -acetyl-5-hydroxytryptamine, buspirone, and sumatriptin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 6. The method of claim 1 wherein said compound acts upon a mid-brain oxytocinergic pathway.
- 7. A method according to claim 6 wherein said compound acting upon a mid-brain oxytocinergic pathway is selected from the group consisting of isotocin, carbetocin, Lys-conopressin, deaminooxytocin, mesotocin, antocin, glumitocin, aspargitocin, valitocin, asvatocin, phasvatocin, and seritocin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 8. The method of claim 1 wherein said compound acts upon a mid-brain nitroxidergic pathway.
- 9. The method according to claim 8 wherein said compound acting upon a mid-brain nitroxidergic pathway is apomoprhine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 10. A method of treating vasculogenic sexual dysfunction in a female in need of such treatment which comprises administering to a patient in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 11. The method of claim 10 wherein said apomorphine is co-administered with a apomorphine-potentiating effective amount of an androgen.
- 12. The method of claim 11 wherein said androgen is selected from the group consisting of testosterone, dihydro-testosterone (DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 13. The method of claim 12 wherein said androgen is selected from testosterone and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 14. The method of claim 11 wherein said apomorphine-potentiating effective amount of androgen and said apomorphine are chronically co-administered.
- 15. The method of claim 11 wherein said apomorphine-potentiating amount of androgen and said apomorphine are co-administered on an as-needed basis.
- 16. The method of claim 11 wherein said apomorphine-potentiating effective amount of androgen is administered prior to the administration of apomorphine.
- 17. The method of claim 11 wherein said androgen is administered concomitantly with the administration of apomorphine.
- 18. A method of inducing effective vasocongestive arousal in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically effective salt, ester, or pro-drug thereof.
- 19. The method of claim 18 wherein said apomorphine is administered prior to sexual activity.
- 20. The method of claim 18 wherein said apomorphine is co-administered with a apomorphine-potentiating effective amount of an androgen.
- 21. The method of claim 20 wherein said androgen is selected from the group consisting of testosterone, dihydrotestosterone (DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 22. The method of claim 21 wherein said androgen is selected from testosterone and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 23. The method of claim 20 wherein said androgen is administered prior to the administration of apomorphine.
- 24. The method of claim 14 wherein said androgen is administered concomitantly with the administration of apomorphine.
- 25. A method of treating vaginal engorgement insufficiency in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester or pro-drug thereof.
- 26. The method of claim 25 wherein said apomorphine is administered prior to sexual activity.
- 27. The method of claim 25 wherein said apomorphine is co-administered with a apomorphine-potentiating effective amount of an androgen.
- 28. The method of claim 27 wherein said androgen is selected from the group consisting of testosterone, dihydrotestosterone (DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 29. The method of claim 28 wherein said androgen is selected from testosterone and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 30. A method of treating clitoral erectile insufficiency in a female in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester or pro-drug thereof.
- 31. The method of claim 30 wherein said apomorphine is administered prior to sexual activity.
- 32. The method of claim 30 wherein said apomorphine is co-administered with a apomorphine-potentiating effective amount of an androgen.
- 33. The method according to claim 32 wherein said androgen is selected from the group consisting of testosterone, dihydrotestosterone (DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 34. The method of claim 33 wherein said androgen is selected from testosterone and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 35. A method of treating vaginal pain comprising administering to a female in need of such treatment a compound which acts upon a dopaminergic, serotonergic, oxytocinergic or nitroxidergic mid-brain neural pathway to stimulate peripheral pelvic non-adrenergic non-cholinergic (NANC) nerve cell release of nitric oxide (NO).
- 36. The method according to claim 35 wherein said compound acts upon a mid-brain dopaminergic pathway.
- 37. The method of claim 36 wherein said compound acting upon a mid-brain dopaminergic pathway is selected from the group consisting of apomorphine, bromocriptine, lisuride, methergoline, pergolide, pribidil and quinapril or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 38. The method of claim 35 wherein said compound acts upon a serotonergic mid-brain pathway.
- 39. A method according to claim 38 wherein said compound acting upon a mid-brain serotonergic pathway is selected from the group consisting of 1-(2,5-dimethoxy-4-iodophenyl)-1-aminopropane, 5-methoxytryptamine, α-methyl-5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine, -acetyl-5-hydroxytryptamine, buspirone, and sumatriptin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 40. The method according to claim 35 wherein said compound acts upon an oxytocinergic mid-brain pathway.
- 41. A method according to claim 40 wherein said compound acting upon a mid-brain oxytocinergic pathway is selected from the group consisting of isotocin, carbetocin, Lys-conopressin, deaminooxytocin, mesotocin, antocin, glumitocin, aspargitocin, valitocin, asvatocin, phasvatocin, and seritocin or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 42. The method of according to claim 35 wherein said compound acts upon a nitroxidergic mid-brain pathway.
- 43. The method according to claim 42 wherein said compound acting upon a mid-brain nitroxidergic pathway is apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 44. A method of treating vaginal pain in a female in need of such treatment which comprises administering to a patient in need of such treatment a therapeutically effective amount of apomorphine of a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 45. The method of claim 44 wherein said apomorphine is co-administered with a apomorphine-potentiating effective amount of an androgen.
- 46. The method of claim 45 wherein said androgen is selected from the group consisting of testosterone, Dehydro-testosterone (DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 47. The method of claim 46 wherein said androgen is testosterone or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 48. The method of claim 45 wherein said apomorphine-potentiating effective amount of androgen or said apomorphine is administered chronically.
- 49. The method of claim 45 wherein said apomorphine-potentiating amount of androgen and said apomorphine are co-administered on an as-needed basis.
- 50. A method of treating dyspareunia in a female in need of such treatment comprising administering, in the interval between about 2 minutes and 120 minutes prior to coitus, a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
- 51. The method of claim 35 wherein said apomorphine is co-administered with a apomorphine-potentiating amount of an androgen.
- 52. The method of claim 51 wherein said androgen is selected from the group consisting of testosterone, dihydrotestosterone (DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 53. The method of claim 52 wherein said androgen is selected from testosterone and pharmaceutically acceptable salts, esters and pro-drugs thereof.
- 54. The method of claim 51 wherein said androgen is administered prior to the administration of apomorphine.
- 55. The method of claim 51 wherein said androgen is administered concomitantly with the administration of apomorphine.
- 56. A method of diagnosing sexual dysfunction in a female patient comprising the steps of;
a) administering apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof; and b) assessing a change in the physiological response in the patient to sexual activity, an improvement indicating sexual dysfunction in said patient.
- 57. The method of claim 56 further comprising the co-administration of an androgen.
- 58. The method of claim 57 wherein said androgen is testosterone or a pharmaceutically effective salt, ester, or pro-drug thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of co-pending application, Ser. No. 09/102,987 filed Jun. 22, 1998 which is a continuation-in-part of application Ser. No. 08/546,498 filed Oct. 20, 1995, now U.S. Pat. No. 5,770,606 which, in turn, is a continuation-in-part of application Ser. No. 08/231,250 filed on Apr. 22, 1994, now abandoned.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09336088 |
Jun 1999 |
US |
Child |
10126933 |
Apr 2002 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09102987 |
Jun 1998 |
US |
Child |
09336088 |
Jun 1999 |
US |
Parent |
08546498 |
Oct 1995 |
US |
Child |
09102987 |
Jun 1998 |
US |
Parent |
08231250 |
Apr 1994 |
US |
Child |
08546498 |
Oct 1995 |
US |